Hot Picks: Eli Lilly leads biotech optimism as weight-loss drugs expand
BNN Bloomberg
Biotech stocks are gaining momentum as weight-loss drugs, pipeline depth and clinical data drive renewed growth optimism.
BNN Bloomberg spoke with Geoff Meacham, global head of healthcare at Citi, about opportunities in large-cap biotech, where established revenue streams and upcoming clinical data could shape the next phase of growth.
Read the full transcript below:
ANDREW: On Hot Picks today, we are focusing on one of our favourite sectors: biotech and pharma. Our guest has Eli Lilly as a top selection. He sees growth for the drug giant amid continued success in the weight-loss drug boom. Let’s get more from Geoff Meacham, global head of healthcare at Citi. Geoff, thanks very much for joining us. You do like the look of Lilly, but is there not a real threat that we’re going to see generic competition emerging in the semaglutide space?
GEOFF: First of all, thanks for having me. I think the market is big enough for multiple players, both generics and branded drugs. I wouldn’t worry too much about generic semaglutide. With Lilly’s injectable business, Zepbound and Mounjaro are both growing nicely. But Orforglipron is really one of the key reasons you want to own this stock. That’s their oral pill, which could launch as early as April, and I think it could really dominate.
ANDREW: And that, of course, is a pill weight-loss drug?
Representatives from Beijing and Washington began their economic and trade talks in Paris on Sunday, Chinese official news agency Xinhua reported.
The impact of the Iran war on fuel prices in Canada may encourage more drivers to go electric, some experts say, but others warn the conflict will drive up prices of "pretty much everything."
The U.S. is temporarily easing some sanctions on Russian oil shipments, reflecting global concerns over sharply higher crude prices due to supply shortages stemming from the Iran war.
The Trump administration this week stepped up its ambitious effort to replace about US$1.6 trillion in lost tariff revenue that was eliminated by the U.S. Supreme Court’s decision to strike down a range of the president’s import taxes.
The Bank of Canada will be balancing a last-minute flood of economic data with uncertainty around trade and war in the Middle East as it prepares to make its second interest rate decision of 2026 this week.
The Trump administration has expanded its trade investigations to 60 countries, including Canada, in an effort to shore up the president’s tariff policies.
Canada has committed to supplying 23.6 million barrels of oil as part of a larger International Energy Agency plan to help stabilize energy markets as the war in the Middle East continues.
Canada’s energy-heavy index may cushion stocks from oil shocks, but rising crude prices could boost inflation and pressure consumers.
Venture Global will proceed with phase 2 of its CP2 liquefied natural gas project in Louisiana, the company said on Friday.
The U.S. is temporarily easing some sanctions on Russian oil shipments, reflecting global concerns over sharply higher crude prices due to supply shortages stemming from the Iran war.
Telus Corp.’s global IT and customer services arm says it’s investigating a breach of its systems.
When Jensen Huang strides onto the stage of a packed hockey arena to kick off Nvidia’s annual developer conference on Monday, he is likely to reveal products and partnerships geared toward keeping the AI chipmaker atop a growing array of competitors.